Research Article
Chenodeoxycholic Acid Derivative HS-1200 Inhibits Hepatocarcinogenesis and Improves Liver Function in Diethylnitrosamine-Exposed Rats by Downregulating MTH1

Miao Xu,1,2 Qi Zhao,1 Donghui Shao,2 Hui Liu,1 Jianni Qi,3 and Chengyong Qin1

1Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, China
2Department of Gastroenterology, Jinan Hospital, Jinan, Shandong 250013, China
3Central Laboratory, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, China

Correspondence should be addressed to Chengyong Qin; chengyongqin2000@163.com

Received 6 September 2016; Accepted 9 January 2017; Published 5 February 2017

Academic Editor: Xin-Yuan Guan

Copyright © 2017 Miao Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Aim. To investigate the effects of HS-1200 on liver tumorigenesis and liver function in a diethylnitrosamine- (DEN-) induced hepatocellular carcinoma (HCC) rat model. Methods. Rats were randomly assigned into five groups: control, HS-1200, HCC, HCC + low dose HS-1200, and HCC + high dose HS-1200 groups. Rat HCC model was established by intraperitoneal injection of DEN. And rats were given HS-1200 by daily oral gavage. After 20 weeks, we examined animal body weight, liver weight, liver pathological changes, serum levels of AST, ALT, and AFP, and mutT homologue gene 1 (MTH1) in liver tissue. Results. Oral gavage of HS-1200 significantly increased animal body weight and decreased liver weight as well as liver coefficient in HCC rats (P < 0.05 versus HCC group). Moreover, oral administration of HS-1200 suppressed tumorigenesis, attenuated pathological changes in liver tissues, and decreased serum levels of AST, ALT, and AFP in HCC rats (P < 0.05 versus HCC group). In addition, the mRNA level of MTH1 was upregulated in the liver tissues of HCC rats (P < 0.05 versus control group), which was reversed by HS-1200 treatment in a dose-dependent manner (P < 0.05 versus HCC group). Conclusions. HS-1200 inhibits hepatocarcinogenesis and improves liver function maybe by inducing downregulation of MTH1.

1. Introduction
Liver cancer is one of the most common malignant tumors and the leading cause of cancer deaths worldwide. An estimated 782,500 new cases of liver cancer and 745,500 liver cancer deaths occurred worldwide in year 2012 [1]. Hepatocellular carcinoma (HCC), which accounts for a majority of primary liver cancers, is generally associated with chronic liver diseases such as hepatitis and cirrhosis [2]. Despite considerable advances in the diagnosis and treatment of primary HCC, the associated mortality rate is still very high due to high metastasis and recurrence rates. At present, the number of drugs used for HCC prevention is quite limited and many of the agents are still undergoing clinical trials [3]. Development of novel treatment options for liver cancer is a key imperative.

Accumulated evidence suggests an anticarcinogenic effect of hydrophilic bile acids such as ursodeoxycholic acid (UDCA). In in vitro cultured HCC cells and in diethylnitrosamine- (DEN-) induced rat HCC model, administration of UDCA appeared to suppress hepatocarcinogenesis by inhibiting cancer cell proliferation [4]. Further, treatment with UDCA was shown to reduce the risk of liver cancer in patients with hepatitis C virus-associated liver cirrhosis [5] and to improve patient prognosis in primary biliary cirrhosis [6]. Chenodeoxycholic acid (CDCA) is the most abundant primary bile acid that is known to decrease dietary cholesterol absorption [7]. HS-1200 {N-[(3a,5b,7a)-3,7-dihydroxy-24-oxocholan-24-yl] b-alanine benzyl ester}, a synthetic CDCA derivative, has shown anticancer activity in several human cancers. For instance, HS-1200 was shown to sensitize breast cancer MCF-7
2. Materials and Methods

2.1. Animals. A total of 125 eight-week-old male Wistar rats, weighing $180 \pm 10$ g, were purchased from Animal Experiment Center of Shandong University. Animals were housed adaptively in the center of the Shandong Provincial Hospital Affiliated to Shandong University for 2 weeks. Fifty rats were used for determining the potential hepatotoxicity and nephrotoxicity of HS-1200. Others were used for the following experiments.

2.2. Evaluation of the Hepatotoxicity and Nephrotoxicity of HS-1200. HS-1200 was provided by College of Chemistry, Shandong Normal University, China. To investigate the potential hepatotoxicity and nephrotoxicity of HS-1200, 50 rats were randomly assigned to five groups based on the dosage of HS-1200: control ($N = 10$), 20 mg/kg HS-1200 ($N = 10$), 40 mg/kg HS-1200 ($N = 10$), 80 mg/kg HS-1200 ($N = 10$), and 100 mg/kg HS-1200 ($N = 10$) group. In HS-1200 groups, animals received daily intragastric administration of different doses of HS-1200 for 40 weeks. Control rats received daily intragastric administration of normal saline solution for the same period. Tail venous blood was collected from each animal for biochemical analysis of liver and renal function every two weeks. Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), albumin (ALB), urea nitrogen (BUN), and creatinine (Cr) were determined using ELISA kits (Shanghai Enzyme-Linked Biotechnology Co., Ltd., China), as per the manufacturer’s instructions. After 40 weeks, animals were sacrificed and the histological changes in liver and kidney examined under light (Olympus, Japan) and electron microscope (JEM-100S, Hitachi, Japan).

2.3. Establishment of Rat Model of Primary Hepatic Carcinoma. Primary hepatic carcinoma model of rat was established by intraperitoneal injection of 2 g/L diethylnitosamine (DEN, Sigma, USA), twice a week for six consecutive weeks. The dose of DEN was initiated from 20 mg/kg and gradually increased until 60 mg/kg (20, 20, 40, 40, 60, and 60 mg/kg). The animals were routinely housed and fed for a total of 20 weeks. No animal deaths occurred during the experiment.

2.4. Experimental Assignment. After 2 weeks of adaptive feeding, rats were randomly assigned to five groups: control ($N = 15$), HS-1200 ($N = 15$), HCC ($N = 15$), HCC + low dose HS-1200 ($N = 15$), and HCC + high dose HS-1200 ($N = 15$) groups. Primary rat HCC model was established as described above. In HCC + low dose HS-1200 or HCC + high dose HS-1200 groups, rats were given HS-1200 by daily oral gavage at a dose of 40 and 80 mg/kg, respectively, for 18 weeks (from 3rd week to 20th week). Control rats received equivalent intraperitoneal injection of normal saline solution for the first six weeks without daily oral gavage of HS-1200. Rats in HS-1200 group were given equivalent intraperitoneal injection of normal saline for the first six weeks and daily oral gavage of 80 mg/kg HS-1200 for 18 weeks (from 3rd week to 20th week). Drugs were administered at the same time every day. Animal body weights were measured at the end of the 20th week.

2.5. Pathological Examination. Rats were sacrificed at the end of the 20th week. The liver was carefully removed and weighed. Liver coefficient was calculated using the following equation:

$$\text{Liver coefficient} (%) = \frac{\text{Liver weight (g)}}{\text{Body weight (g)}}.$$  

Liver samples were fixed and embedded in paraffin. Hematoxylin and eosin (H&E) stained sections were examined under microscope (Olympus, Japan) at a magnification of 200x.
3. Results

3.1. Toxicity Assessment of HS-1200. We assessed the potential hepatotoxicity and nephrotoxicity of HS-1200 treatment in rats. For this purpose, animals received intragastric HS-1200 (daily dose ranging from 0 to 100 mg/kg). Liver function (ALT, AST, GGT, and ALB) (Figure 1) and renal function (BUN, Cr) (Figure 2) were determined in each rats group at all time points. All test results are within the normal range. No significant difference was observed in the liver function and renal function of any of the HS-1200 toxicity assessment groups (P > 0.05 versus control; Figures 1 and 2). After 40 weeks of uninterrupted treatment, pathological examinations were all normal, not necessary to be shown here. So no significant hepatotoxicity or nephrotoxicity was detected in any of the groups. The results suggested that HS-1200 was relatively safe for rats in the dose range of 0 to 100 mg/kg/d. And the dose of 40 and 80 mg/kg/d was decided for treating the rats as low dose and high dose in the next experiment.

3.2. HS-1200 Treatment Inhibits Hepatocarcinogenesis. After treatment with DEN, primary HCC was induced in 93% (14/15) rats. HCC rats exhibited a significant loss of body weight as compared to that in the control group (control, 512 ± 30 g; HCC, 332 ± 52 g; P < 0.05; Figure 3(a)). This was accompanied by significantly greater liver weight and liver coefficient in the HCC rats (P < 0.05 versus control; Figures 3(b) and 3(c)). Low dose and high dose HS-1200 treatment remarkably reduced tumorigenesis by 80% (12/15) and 60% (9/15), respectively. When compared to HCC group, animals receiving low dose or high dose HS-1200 therapy showed increased body weight, reduced liver weight, and decreased liver coefficient (P < 0.05 versus HCC; Figure 1). Moreover, high dose HS-1200 treatment appeared to have a greater efficacy in inhibiting hepatocarcinogenesis (Figure 3). Gross liver examination revealed obvious tumor masses in HCC rats, while in the low dose or high dose HS-1200 groups, tumor growth was suppressed (Figure 4).

3.3. HS-1200 Treatment Attenuated DEN-Induced Pathological Changes in Liver. We next compared the histological findings in liver among the five experimental groups. In the liver tissues obtained from the control or HS-1200 groups, hepatocytes were arranged around the central vein in a radial configuration, and hepatic lobule structures were well preserved (Figures 5(a) and 5(b)). In contrast, disorganized hepatocytes and hepatic lobules, pseudolobule formation, cancer cell nests, and tumor cell atypia were observed in livers of HCC rats (Figure 5(c)). In addition, HCC rats exhibited hepatocyte necrosis as well as severe hepatic inflammatory cell infiltration. In HCC rats receiving low dose of HS-1200 treatment, the cancer cell nest formation and cell necrosis appeared to be much attenuated (Figure 5(d)). High dose of HS-1200 therapy was associated with much improved pathological findings in HCC rats as compared to that observed in rats in the low dose HS-1200 treatment group (Figure 5(e)).

3.4. HS-1200 Prevents Liver Dysfunction in HCC Rats. To evaluate the impact of HS-1200 therapy on liver function, serum levels of ALT, AST, and AFP in rats in the different experimental groups were compared. Serum levels of all three biochemical parameters were significantly elevated in HCC rats (P < 0.05 versus control), which indicated liver dysfunction in these animals (Figure 6). Administration of low or high dose of HS-1200 appeared to reverse the upregulation of serum ALT, AST, and AFP expressions in HCC rats (P < 0.05 versus HCC). Moreover, the serum levels of these parameters were lower in the HCC rats in the high dose HS-1200 group (P < 0.05 versus HCC + low dose HS-1200).

3.5. HS-1200 Downregulates Hepatic mRNA Expression of MTH1 in HCC Rats. To investigate the molecular mechanisms involved in HS-1200-mediated inhibition of tumorigenesis, we examined the mRNA expression of MTH1 in liver tissues. We found significant upregulation of mRNA level of MTH1 in liver tissues of HCC rats (control, 1; HCC, 16.23 ± 0.74; P < 0.05; Figure 7). Further, upregulation of MTH1 mRNA was significantly reversed by low or high dose HS-1200 therapy; high dose appeared to have a higher efficacy in this respect (HCC + low dose HS-1200, 9.48 ± 0.46; HCC + high dose HS-1200, 6.13 ± 0.33; P < 0.05 versus HCC).

4. Discussion

In the present study, a rat primary HCC model was successfully established by DEN injection. Oral administration of
HS-1200 significantly attenuated tumorigenesis and pathological changes in liver tissues, as well as improving liver function of rats exposed to DEN. In addition, the inhibitory role of HS-1200 against HCC positively correlated with the dose of HS-1200.

Although bile acids have been shown to be causative agents in several cancers of the digestive system, including stomach, biliary tract, and colon [25], the precise effect of bile acids on hepatocarcinogenesis is largely unclear. Cholestasis, associated with excessive production of bile acids, is a known etiological factor for liver injury [26]. However, hydrophilic bile acids such as UDCA and CDCA differ in the physicochemical and biological characteristics, and hepatoprotective properties of these subgroups of bile acids have been reported [25]. Liang et al. reported that the CDCA-verticinone ester caused cell cycle arrest, induced ROS generation, and induced cell apoptosis in cultured human liver carcinoma HepG2 cells [27]. The cytotoxic effects of bile acid derivatives, including HS-1183, HS-1199, and HS-1200, have also been demonstrated in in vitro cultured human breast carcinoma cells [28].

In the present study, daily oral gavage of HS-1200 (80 mg/kg) had no significant toxic effect on liver or renal function in rats. However, potential toxicity of HS-1200 at doses over 100 mg/kg/d was not evaluated. Moreover, we demonstrated for the first time the antihapatocarcinogenesis activity of HS-1200 in a primary HCC rat model. Oral gavage of HS-1200 at both low (40 mg/kg/d) and high (80 mg/kg/d)
BUN (toxicity assessment of HS-1200)

Control  80 mg/kg HS-1200 group  20 mg/kg HS-1200 group  40 mg/kg HS-1200 group

Cr (toxicity assessment of HS-1200)

Control  80 mg/kg HS-1200 group  20 mg/kg HS-1200 group  40 mg/kg HS-1200 group

Figure 2: Renal function of HS-1200 toxicity assessment groups. (a) Serum BUN; (b) serum Cr. Data expressed as mean ± SD. * P > 0.05 versus control. BUN, urea nitrogen; Cr, creatinine. HS-1200, N-[(3a,5b,7a)-3,7-dihydroxy-24-oxocholan-24-yl] b-alanine benzyl ester.

dose inhibited tumorigenesis in DEN-exposed rats. These findings are consistent with recent reports which showed that administration of UDCA blocks the in vivo growth and induce apoptosis of BEL7402 cells in mice [29]. In addition, HS-1200 appeared to prevent pathological changes in liver and reversed the elevated serum levels of ALT, AST, and AFP in rats exposed to DEN. The hepatoprotective effect of HS-1200 appears to be dose-dependent as indicated by our results.

By now, we have not found any side effects of HS-1200 in any literature, and no significant hepatotoxicity or nephrotoxicity was detected in any of our experimental groups. A few of the rats with HS-1200 administration suffered from mild diarrhea in the process of experiment. But the diarrhea rats had no obvious mental state change and can tolerate the diarrhea. It might suggest that diarrhea be a potential side effect of HS-1200. We will continue to study it in next research.

DNA damage is very important in the development and progression of liver cancer [30], and MTH1 plays an important role in the repair of DNA oxidative damage. As we mentioned in introduction, 8-OHdG is commonly used biomarker in DNA damage [15]. MTH1’s gene encoding product is a kind of triphosphatase, with a glycosidic enzyme activity. It can hydrolyze 8-OH-dGTP into 8-OH-dGMP in free nucleotides pool and so inhibit 8-OHdG incorporating to DNA chain by mistake, reduce the occurrence of DNA mutations, and then avoid the damage of DNA [31]. Studies have documented that activation of a DNA repair gene MTH1 is required for cancer cells to block incorporation of oxidized dNTPs and thereby prevent ROS-induced DNA damage [18, 32]. MTH1 expression can be increased to eliminate the excess of 8-OHdG produced in oxidative stress [19]. Upregulation of MTH1 has been demonstrated in several types of cancer cells, including in HCC [20–22]. According to the study of Obtułowicz et al., malignant colorectal cancer could cause oxidative stress of tumor cells and promote the upregulation of MTH1 [33]. Borrego et al. found expression level of MTH1 had positive correlation with malignant degree of gastric carcinoma cells [34]. Kennedy et al. indicated that MTH1 was overexpressed in lung cancer cells. And they pointed out MTH1 was necessary for lung cancer cells to remove the damaged DNA structure and maintain the division of cancer cells properly [35]. J¨ungst et al. found that MTH1 expression was significantly higher in liver tumor than corresponding nontumor tissues [23]. MHI can be as an index to reflect DNA repair and ability of oxidative stress of liver cell [36]. Nakabeppu also reported MTH1 inhibitor could increase oxidative damage, increase the cytotoxicity, and induce apoptosis in cancer cells. And he showed MTH1 inhibitor could be a better strategy for treatment of targeting therapy for cancer [37].

Consistent with the current body of evidence, we documented an increased expression of MTH1 mRNA in the liver tissues of rats exposed to DEN. Further, administration of HS-1200 appeared to reverse the upregulation of MTH1 mRNA in a dose-dependent manner. Our findings suggest that HS-1200 may prevent tumorigenesis and protect against liver damage by inducing downregulation of MTH1 and facilitate DNA repair in liver tissues. Indeed, development of small-molecule inhibitors targeting MTH1 has been suggested as a promising strategy for anticancer treatment [18, 38]. However, another issue should also be considered. It has shown MTH1-deficient mice tended to develop liver tumors spontaneously [39] in other studies. Hence, the endogenous level of MTH1 if maintained at a balanced level may minimize tumorigenesis.

In this study, HS-1200 inhibited hepatocarcinogenesis and improved liver function in HCC rats possibly by...
**Figure 3:** Body weight, liver weight, and liver coefficient of study groups. (a) Animal body weight; (b) liver weight; (c) liver coefficient at the end of 20th week. Data expressed as mean ± SD. *P < 0.05 versus control; †P < 0.05 versus HCC; ‡P < 0.05 versus HCC + low dose HS-1200.

HCC, hepatocellular carcinoma; HS-1200, N-[(3a,5b,7a)-3,7-dihydroxy-24-oxocholan-24-yl] b-alanine benzyl ester.

**Figure 4:** Gross liver examination: (a) control; (b) HS-1200; (c) HCC; (d) HCC + low dose HS-1200; (e) HCC + high dose HS-1200. HCC, hepatocellular carcinoma; HS-1200, N-[(3a,5b,7a)-3,7-dihydroxy-24-oxocholan-24-yl] b-alanine benzyl ester.
Figure 5: Histopathologic examination of liver tissues. H&E stained sections of liver specimens were examined under microscope at 200x magnification. (a) Control; (b) HS-1200; (c) HCC; (d) HCC + low dose HS-1200; (e) HCC + high dose HS-1200. H&E, hematoxylin and eosin; HCC, hepatocellular carcinoma; HS-1200, N-[(3a,5b,7a)-3,7-dihydroxy-24-oxocholan-24-yl] b-alanine benzyl ester.

Figure 6: Serum ALT, AST, and AFP levels of study groups. (a) Serum ALT; (b) serum AST; (c) AFP. Data expressed as mean ± SD. * P < 0.05 versus control; † P < 0.05 versus HCC; △ P < 0.05 versus HCC + low dose HS-1200. ALT, alanine aminotransferase; AST, aspartate aminotransferase; AFP, Alpha-fetoprotein. HS-1200, N-[(3a,5b,7a)-3,7-dihydroxy-24-oxocholan-24-yl] b-alanine benzyl ester.
HCC; 24-oxocholan-24-yl\]b-alanine benzylester.

hepatocellular carcinoma; HS-1200, N-[3a,5b,7a)-3,7-dihydroxy-
merase chain reaction; MTH1, mutT homologue gene 1; HCC,
References

This work was supported by grants from the Shan-
Acknowledgments

The authors declare that they have no conflicts of interests.

Competing Interests

The authors declare that they have no conflict of interests.

Acknowledgments

This work was supported by grants from the Shan-
downregulation of MTH1 and enhanced DNA repair. The hepatoprotective effect of HS-1200 showed a positive correlation with its dose. We tentatively suggest that the mechanism may be through the P53 signaling pathways, and future studies are required to further explore the underlying mechanisms that mediate the antitumor and hepatoprotective effect of HS-1200. HS-1200 has earlier been shown to be apoptosis inducer, inhibit cell proliferation, and also be inducer of autophagic cell death in various studies. Along with various other mechanisms, HS-1200 might act through downregulating MTH1 gene as observed in our study.

Competing Interests

The authors declare that they have no conflict of interests.

Acknowledgments

This work was supported by grants from the Shan-
References

[1] L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global cancer statistics, 2012,” CA Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015.

[2] W. T. London and K. A. McGlynn, “Liver cancer,” in Cancer Epidemiology and Prevention, D. Schottenfeld and J. Fraumeni Jr., Eds., pp. 763–786, Oxford University Press, New York, NY, USA, 3rd edition, 2006.

[3] M. Bupathi, A. Kaseb, F. Meric-Bernstam, and A. Naing, “Hepatocellular carcinoma: where there is unmet need,” Molecular Oncology, vol. 9, no. 8, pp. 1501–1509, 2015.

[4] K. Oyama, G. Shiota, H. Ito, Y. Murawaki, and H. Kawasaki, “Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats,” Carcinogenesis, vol. 23, no. 5, pp. 885–892, 2002.

[5] K. Tarao, S. Fujiyama, S. Okhawa et al., “Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 1, pp. 164–169, 2005.

[6] E. M. M. Kuiper, B. E. Hansen, R. A. de Vries et al., “Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid,” Gastroenterology, vol. 136, no. 4, pp. 1281–1287, 2009.

[7] M. P. de Leon, N. Carulli, P. Loria, R. Iori, and F. Zironi, “The effect of ursodeoxycholic acid (CDCA) on cholesterol absorption,” Gastroenterology, vol. 77, no. 2, pp. 223–230, 1979.

[8] S.-B. Yee, Y. S. Song, S. H. Jeong et al., “A novel ursodeoxycholic acid derivative HS-1200 enhances radiation-induced apoptosis in MCF-7 cells,” Oncology Reports, vol. 17, no. 4, pp. 919–923, 2007.

[9] Y. H. Choi, E. O. Im, H. Suh, Y. Jin, Y. H. Yoo, and N. D. Kim, “Apoptosis and modulation of cell cycle control by synthetic derivatives of ursodeoxycholic acid and chenodeoxycholic acid in human prostate cancer cells,” Cancer Letters, vol. 199, no. 2, pp. 157–167, 2003.

[10] S. E. Park, H. J. Choi, S. B. Yee et al., “Synthetic bile acid derivatives inhibit cell proliferation and induce apoptosis in HT-29 human colon cancer cells,” International Journal of Oncology, vol. 25, no. 1, pp. 231–236, 2004.

[11] H. Liu, C.-K. Qin, G.-Q. Han, H.-W. Xu, W.-H. Ren, and C.-Y. Qin, “Synthetic chenodeoxycholic acid derivative, HS-1200, induces apoptosis of human hepatoma cells via a mitochondrial pathway,” Cancer Letters, vol. 270, no. 2, pp. 242–249, 2008.

[12] S. E. Park, S. W. Lee, M. A. Hossain et al., “A chenodeoxycholic acid derivative, HS-1200, induces apoptosis and cell cycle modulation via Egr-1 gene expression control on human hepatoma cells,” Cancer Letters, vol. 270, no. 1, pp. 77–86, 2008.

[13] N. Nishida and M. Kudo, “Oxidative stress and epigenetic instability in human hepatocarcinogenesis,” Digestive Diseases, vol. 31, no. 5-6, pp. 447–453, 2013.

[14] R. Cardin, M. Piciocchi, M. Bortolami et al., “Oxidative damage in the progression of chronic liver disease to hepatocellular carcinoma: an intricate pathway,” World Journal of Gastroenterology, vol. 20, no. 12, pp. 3078–3086, 2014.

[15] D. Ziech, R. Franco, A. Pappa, and M. I. Panayiotidis, “Reactive Oxygen Species (ROS)—induced genetic and epigenetic alterations in human carcinogenesis,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 711, no. 1-2, pp. 167–173, 2011.

[16] M. Chuma, S. Hige, M. Nakaniishi et al., “8-Hydroxy-2′-deoxy-
guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection,” Journal of Gastroenterology and Hepatology, vol. 23, no. 9, pp. 1431–1436, 2008.

[17] Y. Nakabeppu, S. Oka, Z. Sheng, D. Tsuchimoto, and K. Sakumi, “Programmed cell death triggered by nucleotide pool damage and its prevention by MutT homolog-1 (MTH1) with oxidized purine nucleoside triphosphates,” Mutation Research—Genetic Toxicology and Environmental Mutagenesis, vol. 703, no. 1, pp. 51–58, 2010.
[18] H. Gad, T. Koolmeister, A.-S. Jemth et al., “MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool,” Nature, vol. 508, no. 7495, pp. 215–221, 2014.

[19] T. Iida, A. Furuta, Y. Nakabeppu, and T. Iwaki, “Defense mechanism to oxidative DNA damage in glial cells,” Neurpathology, vol. 24, no. 2, pp. 125–130, 2004.

[20] K. Okamoto, S. Toyokuni, W.-J. Kim et al., “Overexpression of human mutT homologue gene messenger RNA in renal-cell carcinoma: evidence of persistent oxidative stress in cancer,” International Journal of Cancer, vol. 65, no. 4, pp. 437–441, 1996.

[21] G. Wani, G. E. Milo, and S. M. D’Ambrosio, “Enhanced expression of the 8-oxo-7,8-dihydrodeoxyguanosine triphosphatase gene in human breast tumor cells,” Cancer Letters, vol. 125, no. 1-2, pp. 123–130, 1998.

[22] S. Koketsu, T. Watanabe, and H. Nagawa, “Expression of DNA repair protein: MYH, NTH1, and MTH1 in colorectal cancer,” Hepato-Gastroenterology, vol. 51, no. 57, pp. 638–642, 2004.

[23] C. Jungst, B. Cheng, R. Gehrke et al., “Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma,” Hepatology, vol. 39, no. 6, pp. 1663–1672, 2004.

[24] N. C. Teoh, Y. Y. Dan, K. Swisshelm et al., “Defective DNA strand break repair causes chromosomal instability and accelerates liver carcinogenesis in mice,” Hepatology, vol. 50, no. 2, pp. 732–741, 2009.

[25] T. Obtułowicz, M. Swoboda, E. Speina et al., “Oxidative stress and 8-oxoguanine repair in human gastric carcinoma: 8-Oxo-7,8-dihydro-2′-deoxyguanosine (8-oxo-dG) as a possible tumor marker,” International Journal of Molecular Sciences, vol. 14, no. 2, pp. 3467–3486, 2013.

[26] Y. Nakabeppu, “Regulation of intracellular localization of human MTH1, OGG1, and MYH proteins for repair of oxidative DNA damage,” Progress in Nuclear Acid Research and Molecular Biology, vol. 68, pp. 75–94, 2001.

[27] Y. Nakabeppu, “Cellular levels of 8-oxoguanine in either DNA or the nucleotide pool play pivotal roles in carcinogenesis and survival of cancer cells,” International Journal of Molecular Sciences, vol. 15, no. 7, pp. 12543–12557, 2014.

[28] K. V. M. Huber, E. Salah, B. Radic et al., “Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy,” Nature, vol. 508, no. 7495, pp. 222–227, 2014.

[29] T. Tsuzuki, A. Egashira, H. Igarashi et al., “Spontaneous tumorigenesis in mice defective in the MTH1 gene encoding 8-oxo-dGTPase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 20, pp. 11456–11461, 2001.